At which stages of breast cancer is neratinib effective? Which stages of breast cancer are suitable for patients?

Neratinib (neratinib) is mainly used for patients with early-stage HER2 positive breast cancer, especially those who have received adjuvant therapy with trastuzumab (Herceptin). HER2Positive breast cancer is highly aggressive and prone to recurrence and metastasis. Clinical studies have shown that neratinib can further reduce the risk of recurrence, especially in patients who still have a high risk of recurrence after surgery, such as HER2-positive patients with more lymph node involvement or hormone receptor-positive patients. Therefore, it is often used in the adjuvant treatment phase to consolidate the results after surgery and primary treatment.

For patients with locally advanced or metastatic HER2-positive breast cancer, neratinib may also be used in certain circumstances, particularly in patients who have received multiple prior lines of HER2-targeted therapy. For example, after receiving treatments such as trastuzumab, pertuzumab, or T-DM1, some patients may still have disease progression, and neratinib may be an option for subsequent treatment. Studies have shown that in these patients, neratinib combined with capecitabine can provide certain clinical benefits.

In the ExteNET clinical trial, patients with early-stage HER2 positive breast cancer received neratinib after completing trastuzumab treatment. One year, it can significantly reduce the disease recurrence rate, especially for hormone receptor-positive (HR+) HER2-positive patients, the risk of recurrence is reduced even more. This shows that neratinib can further consolidate the therapeutic effect and reduce the risk of recurrence caused by residual cancer cells. Therefore, it mainly provides additional protection during the postoperative adjuvant treatment phase and is not suitable for initial treatment.

HER2Patients with positive breast cancer are more likely to develop brain metastasis, and most anti-HER2 drugs cannot effectively penetrate the blood-brain barrier. Neratinib has shown potential benefit in some studies for patients with breast cancer brain metastases due to its strong irreversible HER2 inhibition. Although the evidence for its use alone for brain metastases still requires further study, in some cases, doctors may consider using it in patients with HER2-positive breast cancer who are at risk of brain metastases to delay disease progression as much as possible.

Reference:https://en.wikipedia.org/wiki/Neratinib